Oneview Healthcare (ONE) H1 2025 earnings summary

Executive summary

• Revenue increased 36% year-over-year to €6.3m in H1 2025, driven by US market expansion, new deployments, and customer wins.

• Launched Ovie, a Gen AI-powered care assistant, and embedded AI-powered solutions across business functions, achieving ISO 42001 certification for AI management.

• Restructuring in June 2025 led to a 10% global headcount reduction, mainly in Australia, with expected annual cost savings of €1.1m.

• Secured two new customer logos and a three-year contract extension with a major customer, expected to deliver over 20% annual recurring revenue growth from that account.

• No interim dividend declared for the period.

Financial highlights

• H1 2025 revenue reached €6.3m, up 36% year-over-year; recurring revenue was €3.8m (+7%), non-recurring revenue €2.5m (+131%).

• Gross margin declined to 61% from 73% in H1 2024 due to a higher mix of lower-margin hardware deployments and increased non-recurring revenue.

• Operating EBITDA loss was €4.5m, with net loss after tax of €7.9m, impacted by FX losses and higher staff costs.

• Cash balance at June 30, 2025, was €8.2m.

• Cash operating expenses rose 17% to €8.3m, reflecting investments in deployment resources and product development.

Outlook and guidance

• Management expects lower cash burn in H2 2025 due to restructuring benefits and seasonally stronger cash receipts.

• Targeting 15,000 live endpoints by December 2025, with upside potential if additional contracts close and deploy within the year.

• New front-end user experience and further AI-powered products to be delivered in H2 2025.

• Focus on operational efficiency and standardized 90-day deployment cycles.

• Directors believe existing cash and working capital are sufficient to fund operations for at least 12 months, though sales conversion uncertainty remains.